<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03132337</url>
  </required_header>
  <id_info>
    <org_study_id>1701020549</org_study_id>
    <nct_id>NCT03132337</nct_id>
  </id_info>
  <brief_title>Sinusoidal Obstruction Syndrome for Stem Cell Transplant Patients Biomarker Study</brief_title>
  <acronym>SOSBiomarker</acronym>
  <official_title>Biomarkers of Endothelial Dysfunction in Pediatric Patients Receiving High Intensity Chemotherapy/Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this is to learn more about stem cell transplant and complications that some&#xD;
      people have after their transplants, in particular sinusoidal obstruction syndrome (SOS),&#xD;
      also called veno-occlusive disease of the liver.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective, observational trial. We will measure biomarkers and&#xD;
      determine thresholds that will predict increased risk for SOS in pediatric patients receiving&#xD;
      HCT or high intensity chemotherapy/irradiation with the future goal of a randomized,&#xD;
      interventional, open-label, multicenter trial that will test the preemptive use of&#xD;
      defibrotide for prevention of SOS in an enriched high-risk population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SOS proteomic markers</measure>
    <time_frame>Until the end of the study evaluation, day 180</time_frame>
    <description>Measure for 3 SOS proteomic markers, L-Ficolin, HA, and ST2, as early predictors of SOS incidence through study completion.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sinusoidal Obstruction Syndrome</condition>
  <arm_group>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <description>Serial Blood Draws</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serial Blood Draws</intervention_name>
    <description>Day 0 and Day 3 blood draw for SOS biomarkers. If subject develops SOS blood draw prior to dose of Defibrotide, Day 14 after Defibrotide and Day 21 after Defibrotide.</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stem Cell Transplant patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age ≤ 25 years undergoing HCT for any reason who fulfill any ONE (1) of the following&#xD;
        criteria:&#xD;
&#xD;
          1. History of hepatic disease as defined by:&#xD;
&#xD;
               1. Viral hepatitis (i.e., hepatitis C virus [HCV])&#xD;
&#xD;
               2. Liver tumor before HCT&#xD;
&#xD;
               3. Hepatic fibrosis or cirrhosis before HCT as proven by liver biopsy&#xD;
&#xD;
               4. High aspartate aminotransferase (AST) (&gt; 2x ULN) before HCT (pre-transplant&#xD;
                  evaluation)&#xD;
&#xD;
               5. High alanine transaminase (ALT) (&gt; 2x ULN) before HCT&#xD;
&#xD;
               6. High bilirubin (&gt; 1.2x ULN) before HCT&#xD;
&#xD;
          2. HCT high-risk features including:&#xD;
&#xD;
             a. Conditioning with high-risk modalities including: i. Busulfan (BU)-containing&#xD;
             regimen particularly with oral BU + cyclophosphamide ii. TBI-containing regimen,&#xD;
             particularly cyclophosphamide + total-body irradiation (TBI) b. ≥ 2 HCT c. Allo-HCT&#xD;
             for leukemia &gt; or = second relapse d. Unrelated donor (URD) HCT e. Human leukocyte&#xD;
             antigen (HLA) mismatch HCT (less than 10 of 10 for bone marrow/peripheral blood stem&#xD;
             cell [BM/PBSC] or anything less than 6 of 6 for UCB) f. Use of sirolimus + tacrolimus&#xD;
             prophylaxis for GVHD&#xD;
&#xD;
          3. High-risk disease states including:&#xD;
&#xD;
               1. Juvenile myelo-monocytic chronic leukemia (JMML)&#xD;
&#xD;
               2. Primary hemophagocytic lymphohistiocytosis (HLH)&#xD;
&#xD;
               3. Adrenoleukodystrophy&#xD;
&#xD;
               4. Osteopetrosis&#xD;
&#xD;
          4. Other high-risk features including:&#xD;
&#xD;
               1. Prior treatment with gemtuzumab ozogamicin&#xD;
&#xD;
               2. Use of hepatotoxic drugs 1 month before HCT and during HCT&#xD;
&#xD;
               3. Iron overload (i.e., thalassemia/sickle cell) with serum ferritin &gt; 1000ng/ml&#xD;
&#xD;
               4. Deficit of ATIII, T-PA (i.e., &lt; 30% normal values), and resistance to activated&#xD;
                  protein C if clinical indication (these values do not have to be specifically&#xD;
                  checked if no clinical history)&#xD;
&#xD;
               5. Young age &lt; 2 years but more than 1 month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who are transplanted but do not fulfill any of the above mentioned criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Sophie Paczesny</investigator_full_name>
    <investigator_title>Professor, Department of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Veno-Occlusive Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

